Several studies have demonstrated that a combination strategy of an HDAC inhibitor with a TRAIL sensitizer has emerged as a potent strategy to prime cancer cells to TRAIL-mediated apoptosis in a variety of human cancers [48]. The gene discussed is HDAC9; the disease is cancer.